Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Pharmaco-genomics Pharmaco-metabolomics Pharmaco-transcriptomics Pharmaco-proteomics Search

Displaying entries 79751 - 79775 of 102031 in total

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome	References
							Clear
Titanium dioxide	Approved	TLR6	10333	upregulated	titanium dioxide results in increased expression of TLR6 mRNA	4p14	A24217
Titanium dioxide	Approved	TNF	7124	upregulated	titanium dioxide results in increased expression of TNF mRNA	6p21.33	A24434
Titanium dioxide	Approved	TNFRSF1A	7132	downregulated	titanium dioxide results in decreased expression of TNFRSF1A mRNA	12p13.31	A24434 A24217
Titanium dioxide	Approved	TOLLIP	54472	downregulated	titanium dioxide results in decreased expression of TOLLIP mRNA	11p15.5	A24217
Titanium dioxide	Approved	TOP2A	7153	downregulated	[Vitallium analog binds to titanium dioxide] which results in decreased expression of TOP2A mRNA	17q21.2	A24432
Titanium dioxide	Approved	TP53	7157	upregulated	titanium dioxide results in increased expression of TP53 mRNA	17p13.1	A24434 A24437
Titanium dioxide	Approved	TRAF6	7189	downregulated	titanium dioxide results in decreased expression of TRAF6 mRNA	11p12	A24217
Titanium dioxide	Approved	TYMS	7298	downregulated	[Vitallium analog binds to titanium dioxide] which results in decreased expression of TYMS mRNA	18p11.32	A24432
Titanium dioxide	Approved	VCAM1	7412	upregulated	titanium dioxide results in increased expression of VCAM1 mRNA	1p21.2	A24442
Tofacitinib	Approved Investigational	CCL2	6347	downregulated	tofacitinib results in decreased expression of CCL2 mRNA	17q12	A24443
Tofacitinib	Approved Investigational	CCND1	595	upregulated	tofacitinib results in increased expression of CCND1 mRNA	11q13.3	A23049
Tofacitinib	Approved Investigational	CXCL10	3627	downregulated	tofacitinib results in decreased expression of CXCL10 mRNA	4q21.1	A24443
Tofacitinib	Approved Investigational	CXCL13	10563	downregulated	tofacitinib results in decreased expression of CXCL13 mRNA	4q21.1	A24443
Tofacitinib	Approved Investigational	KRT16	3868	downregulated	tofacitinib results in decreased expression of KRT16 mRNA	17q21.2	A24444
Tofacitinib	Approved Investigational	MMP1	4312	downregulated	tofacitinib results in decreased expression of MMP1 mRNA	11q22.2	A24443
Tofacitinib	Approved Investigational	MMP3	4314	downregulated	tofacitinib results in decreased expression of MMP3 mRNA	11q22.2	A24443
Tofacitinib	Approved Investigational	VEGFA	7422	upregulated	tofacitinib results in increased expression of VEGFA mRNA	6p21.1	A23049
Tolbutamide	Approved	PDCD4	27250	downregulated	Tolbutamide results in decreased expression of PDCD4 mRNA	10q25.2	A21681
Tolbutamide	Approved	PDCD4	27250	upregulated	Tolbutamide results in increased expression of PDCD4 mRNA	10q25.2	A21681
Tolbutamide	Approved	TNFAIP3	7128	downregulated	Tolbutamide results in decreased expression of TNFAIP3 mRNA	6q23.3	A21681
Tolbutamide	Approved	TPD52	7163	downregulated	Tolbutamide results in decreased expression of TPD52 mRNA	8q21.13	A21681
Tolbutamide	Approved	TPD52	7163	upregulated	Tolbutamide results in increased expression of TPD52 mRNA	8q21.13	A21681
Tolfenamic acid	Approved	PSMB10	5699	upregulated	tolfenamic acid results in increased expression of PSMB10 mRNA	16q22.1	A22208
Tolfenamic acid	Approved	PSMB9	5698	upregulated	tolfenamic acid results in increased expression of PSMB9 mRNA	6p21.32	A22208
Tolnaftate	Approved Vet Approved	IL4	3565	downregulated	Tolnaftate results in decreased expression of IL4 mRNA	5q31.1	A23096 A23097

Displaying entries 79751 - 79775 of 102031 in total

Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Advanced Filter

Filter by Group

Filter by Market Availability